COMMUNIQUÉS West-GlobeNewswire

FLYTE EXPANDS STRATEGIC RELATIONSHIP WITH VOLATO BY JOINING VAUNT PLATFORM
11/06/2026
Flyte to expand private aviation demand, increase aircraft utilization, and accelerate revenue growth Flyte Gains Access to Fast-Growing Private Aviation Membership Network While Unlocking New Revenue Opportunities [...]
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
11/06/2026
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD [...]
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
11/06/2026
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency [...]
TOMI Environmental Solutions Highlights Massive Biosecurity Opportunity Ahead of FIFA World Cup
11/06/2026
Largest Sporting Event in History Expected to Bring Millions of Travelers Across Three Countries, Highlighting Growing Need for Advanced Large-Scale Disinfection and Decontamination FREDERICK, Md., June 11, 2026 (GLOBE [...]
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
11/06/2026
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors MELBOURNE, Australia, June 11, 2026 ( [...]
Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress
11/06/2026
Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients Global TENACITY-01 study reports 86% overall response rate in adults with R/R T-ALL/LBL BOSTON, June 11, 2026 (GLOBE NEWSWIRE [...]
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
11/06/2026
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease VANCOUVER, Washington, June 11, 2026 (GLOBE NEWSWIRE [...]
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
11/06/2026
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that [...]
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
11/06/2026
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
11/06/2026
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“ [...]
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
11/06/2026
PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May Help to Optimize Therapeutic Response Monitoring Following Treatment Delivered [...]
Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com
11/06/2026
My Grief Angels Inc. launches a first-of-its-kind Father’s Day grief support initiative — a complete, free bundle of resources assembled by bereaved mothers, for bereaved fathers. New York, NY, June 11, 2026 (GLOBE [...]
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
11/06/2026
BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with favorable pharmacokinetic properties SAN [...]
Clinical Data Showed Average 67% Pain Score Reduction and 50% Gain in Walking Distance with Cartigenix HP® in 90 Days*†
11/06/2026
A randomized, placebo-controlled study published in Pharmaceutical Research documented a 64% reduction in WOMAC pain scores and measurable cartilage regeneration biomarkers at 90 days, a first for the joint health [...]
What Science-Backed Subscription Health Programs Measure Differently
11/06/2026
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the [...]
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
11/06/2026
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026) [...]
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
11/06/2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive [...]
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
11/06/2026
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall [...]
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
11/06/2026
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorder Five scientific presentations will feature preclinical and clinical data [...]

Pages